A public biopharmaceutical company listed on Alternext (Paris), GENFIT is focused on the development of innovative therapeutic and diagnostic solutions for prevention and treatment of diabetes and related disorders.

EARLY DIAGNOSIS, PREVENTION AND TREATMENT OF CARDIOMETABOLIC DISEASES

With its strong position within the Lille (France) research hub dedicated to cardiometabolic diseases and personalized medicine, and numerous collaborations with academic research institutes and other biotechnology companies, GENFIT has developed the entire spectrum of R&D skills, from the discovery of new therapeutic targets or biomarker candidates to Phase II clinical trials.

GENFIT applies its know-how in the field of cardiometabolic diseases to the conception and the development of new drug candidates, both inhouse and for its industrial partners, always with the aim of satisfying medical needs that are not entirely met by current diagnostic methods and treatment strategies.

GENFIT, A MAJOR PLAYER IN THE DEVELOPMENT OF DIAGNOSTIC AND THERAPEUTIC SOLUTIONS FOR DIABETES

Created in 1999, listed on the Alternext market of NYSE (Euronext, Paris) since 2006

  • Vocation: To bring therapeutic and diagnostic solutions to the pharmaceutical industry to combat the major health concerns of diabetes, its associated risk factors, and its complications
  • Employees: 90
  • Intellectual Property: 250 patents/patent applications, of which 135 have been granted
  • Location:
  • Headquartered in Lille (France)
  • Subsidiary in Cambridge (USA)
  • 7000m2 state-of-the-art laboratories

GENFIT CORP.: AN INTERNATIONAL PRESENCE

GENFIT is committed to partnering with academia, biotechnology and pharmaceutical companies worldwide. Genfit Corp., based in Cambridge (MA), is our local interface with leading institutes and companies in the North American marketplace. Our proximity to this world-renowned hub between the academic research community, leading hospitals and local biopharma firms offers many competitive advantages. The combination of technology and medicine makes this the perfect environment for therapeutic biotechnological innovation. Genfit Corp. participates in leading national pharma events, leveraging its strategic location and our scientific expertise to develop and expand academic and industry collaborative opportunities in the USA.

Download the 2011 Company Fact Sheet